Cell death inhibiting RNA (CDIR) modulates IFN-γ-stimulated sensitization to Fas/CD95/Apo-1 and TRAIL/Apo-2L-induced apoptosis

Cell Cycle

Volumn 3, Issue 12, 2004, Pages 1606-1611

  Shchors, Ksenya ^a,b   Yehiely, Fruma ^a   Deiss, Louis P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 UTR; Apoptosis; AU rich; Fas; Interferon ; IRF 1; KIAA0425; Sensitization; STAT 1; TRAIL

Indexed keywords

CELL DEATH INHIBITING RNA; FAS ANTIGEN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA CONVERTING ENZYME; RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; PROTEIN INDUCTION; SENSITIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 17144391817     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.12.1295     Document Type: Article

References (65)

1. Metzstein MM, Stanfield GM, Horvitz HR. Genetics of programmed cell death in C. elegans: Past, present and future. Trends Genet 1998; 14:410-6.
2. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10:1-15.
3. Green DR. Apoptotic pathways: The roads to ruin. Cell 1998; 94:695-8.
4. Rudin CM, Thompson CB. Apoptosis and disease: Regulation and clinical relevance of programmed cell death. Annu Rev Med 1997; 48:267-81.
5. Brunner T, Mueller C. Apoptosis in disease: About shortage and excess. Essays Biochem 2003; 39:119-30.
6. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281:1305-8.
7. Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331-67.
8. Zornig M, Hueber A, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001; 1551:F1-37.
9. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998; 12:1551-70.
10. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1997; 326:1-16.
11. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33:29-55.
12. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000; 32:1123-36.
13. Kalvakolanu DV. Interferons and cell growth control. Histol Histopathol 2000; 15:523-37.
14. Akhurst RJ, Derynck R. TGF-β signaling in cancer - a double-edged sword. Trends Cell Biol 2001; 11:S44-51.
15. Wakefield LM, Roberts AB. TGF-β signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12:22-9.
16. Darnell Jr JE. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998; 18:549-54.
17. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-64.
18. Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator in IFN-γ-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 1999; 257:672-7.
19. Ikeda H, Old LJ, Schreiber RD. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13:95-109.
20. Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to nontoxic cancer therapeutics (review). Int J Oncol 1999; 15:793-802.
21. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-61.
22. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49.
23. Ismail A, Van Groeningen CJ, Hardcastle A, et al. Modulation of fluorouracil cytotoxicity by interferon-α and -γ. Mol Pharmacol 1998; 53:252-61.
24. Ossina NK, Cannas A, Powers VC, et al. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 272:16351-7.
25. Deiss LP, Kimchi A. A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal. Science 1991; 252:117-20.
26. Langaas V, Shahzidi S, Johnsen JI, et al. Interferon-γ modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res 2001; 21:3733-8.
27. Ruiz-Ruiz C, Lopez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-γ in human breast tumour cells. Biochem J 2002; 365:825-32.
28. Park SY, Billiar TR, Seol DW. IFN-γ inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-γ-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 2002; 291:233-6.
29. Fellenberg J, Mau H, Scheuerpflug C, et al. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Int J Cancer 1997; 72:536-42.
30. Koshiji M, Adachi Y, Sogo S, et al. Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-α (TNF-α) and/or interferon-γ (IFN-γ), resulting from down-modulation of Bcl-2 expression. Clin Exp Immunol 1998; 111:211-8.
31. Liu K, Abrams SI. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-γ. J Immunol 2003; 170:6329-37.
32. Spanaus KS, Schlapbach R, Fontana A. TNF-α and IFN-γ render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and downregulation of Bcl-2 and Bcl-xL. Eur J Immunol 1998; 28:4398-408.
33. Shin EC, Shin WC, Choi Y, et al. Effect of interferon-γ on the susceptibility to Fas (CD95/APO-1)-mediated cell death in human hepatoma cells. Cancer Immunol Immunother 2001; 50:23-30.
34. Choi C, Jeong E, Benveniste EN. Caspase-1 mediates Fas-induced apoptosis and is upregulated by interferon-γ in human astrocytoma cells. J Neurooncol 2004; 67:167-76.
35. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-62.
36. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 256:58-66.
37. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo21/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001; 7:1362-9.
38. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998; 92:1735-42.
39. Smedley D, Hamoudi R, Lu YJ, et al. Cloning and mapping of members of the MYM family. Genomics 1999; 60:244-7.
40. Sohal J, Reiter A, Goldman JM, Cross NC. Cloning of ZNF237, a novel member of the MYM gene family that maps to human chromosome 13q11 - >q12. Cytogenet Cell Genet 2000; 89:24-8.
41. Macdonald D, Aguiar RC, Mason PJ, et al. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: A review. Leukemia 1995; 9:1628-30.
42. van der Maarel SM, Scholten IH, Huber I, et al. Cloning and characterization of DXS6673E, a candidate gene for X-linked mental retardation in Xq13.1. Hum Mol Genet 1996; 5:887-97.
43. McDoniels-Silvers AL, Nimri CF, Stoner GD, et al. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002; 8:1127-38.
44. Shchors K, Yehiely F, Kular RK, et al. Cell death inhibiting RNA (CDIR) derived from a 3′-untranslated region binds AUF1 and heat shock protein 27. J Biol Chem 2002; 277:47061-72.
45. Deiss LP, Feinstein E, Berissi H, et al. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the γ interferon-induced cell death. Genes Dev 1995; 9:15-30.
46. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000; 60:5673-80.
47. Sedger LM, Shows DM, Blanton RA, et al. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163:920-6.
48. Griffith TS, Wiley SR, Kubin MZ, et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189:1343-54.
49. Raveh T, Kimchi A. DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res 2001; 264:185-92.
50. Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000; 10:73-81.
51. Nozawa H, Oda E, Nakao K, et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 1999; 13:1240-5.
52. Rastinejad F, Blau HM. Genetic complementation reveals a novel regulatory role for 3′ untranslated regions in growth and differentiation. Cell 1993; 72:903-17.
53. Rastinejad F, Conboy MJ, Rando TA, Blau HM. Tumor suppression by RNA from the 3′ untranslated region of α-tropomyosin. Cell 1993; 75:1107-17.
54. Jupe ER, Liu XT, Kiehlbauch JL, et al. The 3′ untranslated region of prohibitin and cellular immortalization. Exp Cell Res 1996; 224:128-35.
55. Fan H, Villegas C, Huang A, Wright JA. Suppression of malignancy by the 3′ untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res 1996; 56:4366-9.
56. Powell AJ, Gates PB, Wylie D, et al. Immortalization of rat embryo fibroblasts by a 3′-untranslated region. Exp Cell Res 1998; 240:252-62.
57. Bevilacqua A, Ceriani MC, Capaccioli S, Nicolin A. Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol 2003; 195:356-72.
58. Zhang T, Kruys V, Huez G, Gueydan C. AU-rich element-mediated translational control: Complexity and multiple activities of trans-activating factors. Biochem Soc Trans 2002; 30:952-8.
59. Paste M, Huez G, Kruys V. Deadenylation of interferon-β mRNA is mediated by both the AU-rich element in the 3′-untranslated region and an instability sequence in the coding region. Eur J Biochem 2003; 270:1590-7.
60. Tebo J, Der S, Frevel M, et al. Heterogeneity in control of mRNA stability by AU-rich elements. J Biol Chem 2003; 278:12085-93.
61. Bakheet T, Williams BR, Khabar KS. ARED 2.0: An update of AU-rich element mRNA database. Nucleic Acids Res 2003; 31:421-3.
62. Fulda S, Debatin KM. IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002; 21:2295-308.
63. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004; 23:3051-60.
64. Kim K, Takimoto R, Dicker DT, et al. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 2001; 18:241-7.
65. Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemoth1611erapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002; 99:491-504.